Literature DB >> 12814248

Characterization of 9L glioma model of the Wistar rat.

Maja Stojiljkovic1, Vesna Piperski, Mirjana Dacevic, Ljubisav Rakic, Sabera Ruzdijic, Selma Kanazir.   

Abstract

The aim of our study was to develop and characterize solid brain tumors in Wistar rats, which could be used in investigations concerning the molecular mechanisms that lay beneath the genesis of the gliomas as well as in the testing of curative potentials of various therapeutics. The tumors were induced by intracerebral inoculation of 9L glioma cells and characterized by morphometrical, histological and immunohistochemical analysis after 7, 14 and 21 postimplantation days. Immunohistochemical characterization included detection of the nuclear antigene Ki-67 as the proliferative cell marker, GFAP as a tracer of reactive gliosis surrounding the tumor mass, and CD4/CD8 and ED1 antigens, as markers of the immunological response. Our results showed that after 7 days all experimental animals developed solid, well-circumcised tumors, which were clearly separated from the surrounding brain tissue. Tumors showed progressive growth from the 7th to the 21st day despite the observed immunological response starting after 14 days. Histologically tumors were hypercellular with neovascularization and necrosis. These results indicate that reproducible morphometric evaluation can be performed on 9L tumors growing in immunocompetent Wistar rats, enabling its use as an animal tumor model for the evaluation of various therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814248     DOI: 10.1023/a:1023732619651

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Endothelial cell-based cytokine gene delivery inhibits 9L glioma growth in vivo.

Authors:  M Nam; P Johnston; B Lal; R Indurti; M A Wilson; J Laterra
Journal:  Brain Res       Date:  1996-08-26       Impact factor: 3.252

2.  Morphometrical characterization of two glioma models in the brain of immunocompetent and immunodeficient rats.

Authors:  M Saini; M Bellinzona; F Meyer; G Cali; M Samii
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

3.  p16INK4a and p19INK4d mRNA expression in neuroglial tumours: correlation with Ki67 proliferation index.

Authors:  C Bouvier-Labit; M Civatte; C Bartoli; W Renaud; J F Pellissier; D Figarella-Branger
Journal:  Neuropathol Appl Neurobiol       Date:  1999-10       Impact factor: 8.090

4.  Radiosurgery and fractionated radiation therapy: comparison of different techniques in an in vivo rat glioma model.

Authors:  D Kondziolka; S Somaza; C Comey; L D Lunsford; D Claassen; S Pandalai; A Maitz; J C Flickinger
Journal:  J Neurosurg       Date:  1996-06       Impact factor: 5.115

5.  Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index.

Authors:  S W Coons; P C Johnson
Journal:  J Neuropathol Exp Neurol       Date:  1993-11       Impact factor: 3.685

6.  Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma.

Authors:  V Cool; B Pirotte; C Gérard; J L Dargent; N Baudson; M Levivier; S Goldman; J Hildebrand; J Brotchi; T Velu
Journal:  Hum Gene Ther       Date:  1996-03-20       Impact factor: 5.695

7.  Assessment of brain tumor cell motility in vivo and in vitro.

Authors:  M R Chicoine; D L Silbergeld
Journal:  J Neurosurg       Date:  1995-04       Impact factor: 5.115

8.  Correlation between Gd-enhanced MR imaging and histopathology in treated and untreated 9L rat brain tumors.

Authors:  D E Wilkins; G P Raaphorst; J K Saunders; G R Sutherland; I C Smith
Journal:  Magn Reson Imaging       Date:  1995       Impact factor: 2.546

9.  Experimental glioma in primates: a computed tomography model.

Authors:  K G Rieth; G Di Chiro; W T London; J L Sever; S A Houff; P L Kornblith; P E McKeever; C Buonomo; B L Padgett; D L Walker
Journal:  J Comput Assist Tomogr       Date:  1980-06       Impact factor: 1.826

10.  Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.

Authors:  C A Kruse; D H Mitchell; B K Kleinschmidt-DeMasters; D Bellgrau; J M Eule; J R Parra; Q Kong; K O Lillehei
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

View more
  16 in total

1.  In vivo observation of intracellular oximetry in perfluorocarbon-labeled glioma cells and chemotherapeutic response in the CNS using fluorine-19 MRI.

Authors:  Deepak K K Kadayakkara; Jelena M Janjic; Lisa K Pusateri; Won-Bin Young; Eric T Ahrens
Journal:  Magn Reson Med       Date:  2010-09-21       Impact factor: 4.668

Review 2.  Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Authors:  Rolf F Barth; Balveen Kaur
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

3.  Characterization of the 9L gliosarcoma implanted in the Fischer rat: an orthotopic model for a grade IV brain tumor.

Authors:  Audrey Bouchet; Marie Bidart; Imen Miladi; Céline Le Clec'h; Raphaël Serduc; Charles Coutton; Pierrick Regnard; Enam Khalil; Sandrine Dufort; Benjamin Lemasson; Jean Laissue; Laurent Pelletier; Géraldine Le Duc
Journal:  Tumour Biol       Date:  2014-03-16

4.  Evans blue nanocarriers visually demarcate margins of invasive gliomas.

Authors:  Benjamin T Roller; Jennifer M Munson; Barunashish Brahma; Philip J Santangelo; S Balakrishna Pai; Ravi V Bellamkonda
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

5.  Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model.

Authors:  Annabelle Cikankowitz; Anne Clavreul; Clément Tétaud; Laurent Lemaire; Audrey Rousseau; Nicolas Lepareur; Djamel Dabli; Francis Bouchet; Emmanuel Garcion; Philippe Menei; Olivier Couturier; François Hindré
Journal:  J Neurooncol       Date:  2016-10-25       Impact factor: 4.130

6.  A tubulin binding peptide targets glioma cells disrupting their microtubules, blocking migration, and inducing apoptosis.

Authors:  Raphael Berges; Julien Balzeau; Alan C Peterson; Joel Eyer
Journal:  Mol Ther       Date:  2012-04-10       Impact factor: 11.454

7.  Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes.

Authors:  Christopher L Mariani; Joshua G Kouri; Wolfgang J Streit
Journal:  J Neurooncol       Date:  2006-04-13       Impact factor: 4.130

8.  Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme.

Authors:  Drazen Zagorac; Danica Jakovcevic; Debebe Gebremedhin; David R Harder
Journal:  J Cereb Blood Flow Metab       Date:  2008-04-16       Impact factor: 6.200

9.  Longitudinal evaluation of tumor microenvironment in rat focal brainstem glioma using diffusion and perfusion MRI.

Authors:  Kulam Najmudeen Magdoom; Francisco Delgado; Ana C Bohórquez; Alec C Brown; Paul R Carney; Carlos Rinaldi; Thomas H Mareci; James R Ewing; Malisa Sarntinoranont
Journal:  J Magn Reson Imaging       Date:  2018-10-14       Impact factor: 4.813

10.  The translocator protein ligand [¹⁸F]DPA-714 images glioma and activated microglia in vivo.

Authors:  Alexandra Winkeler; Raphael Boisgard; Ali R Awde; Albertine Dubois; Benoit Thézé; Jinzi Zheng; Luisa Ciobanu; Frédéric Dollé; Thomas Viel; Andreas H Jacobs; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.